[go: up one dir, main page]

AR045972A1 - FORMULATIONS OF RELEASE OF SUSTAINED LIBERATION WITH EFFECTIVENESS OF 24 HOURS - Google Patents

FORMULATIONS OF RELEASE OF SUSTAINED LIBERATION WITH EFFECTIVENESS OF 24 HOURS

Info

Publication number
AR045972A1
AR045972A1 ARP030103926A ARP030103926A AR045972A1 AR 045972 A1 AR045972 A1 AR 045972A1 AR P030103926 A ARP030103926 A AR P030103926A AR P030103926 A ARP030103926 A AR P030103926A AR 045972 A1 AR045972 A1 AR 045972A1
Authority
AR
Argentina
Prior art keywords
hours
release
formulations
effectiveness
sustained liberation
Prior art date
Application number
ARP030103926A
Other languages
Spanish (es)
Original Assignee
Labopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32179487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR045972(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Labopharm Inc filed Critical Labopharm Inc
Publication of AR045972A1 publication Critical patent/AR045972A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica oral para la liberación controlada de tramadol que se administra una vez por día. Reivindicación 1: Una composión farmacéutica para la liberación controlada de tramadol o una sal del mismo, que se administra una vez por día, caracterizada porque al administrarse inicialmente una dosis, proporciona un inicio del efecto analgésico en 2 horas, donde dicho efecto analgésico continua por al menos 24 horas después de la administración.Oral pharmaceutical composition for controlled release of tramadol that is administered once a day. Claim 1: A pharmaceutical composition for the controlled release of tramadol or a salt thereof, which is administered once a day, characterized in that when a dose is initially administered, it provides an onset of the analgesic effect in 2 hours, wherein said analgesic effect continues for at least 24 hours after administration.

ARP030103926A 2002-10-25 2003-10-27 FORMULATIONS OF RELEASE OF SUSTAINED LIBERATION WITH EFFECTIVENESS OF 24 HOURS AR045972A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28102602A 2002-10-25 2002-10-25
US51037803P 2003-10-10 2003-10-10

Publications (1)

Publication Number Publication Date
AR045972A1 true AR045972A1 (en) 2005-11-23

Family

ID=32179487

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103926A AR045972A1 (en) 2002-10-25 2003-10-27 FORMULATIONS OF RELEASE OF SUSTAINED LIBERATION WITH EFFECTIVENESS OF 24 HOURS

Country Status (11)

Country Link
JP (1) JP2006507277A (en)
KR (1) KR20050083816A (en)
AR (1) AR045972A1 (en)
AU (1) AU2003275855B2 (en)
CA (1) CA2503155A1 (en)
IL (1) IL168114A (en)
NO (1) NO20052479L (en)
PT (1) PT1594460E (en)
RU (1) RU2328275C2 (en)
UA (1) UA84277C2 (en)
WO (1) WO2004037222A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US7413749B2 (en) 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
EP1905435A3 (en) * 2003-03-11 2008-05-14 Euro-Celtique S.A. Titration dosing regimen for controlled release tramadol
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
AU2005245403B2 (en) * 2004-05-14 2012-04-19 Janssen Pharmaceutica N.V. Carboxamido opioid compounds
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
BRPI0615860B8 (en) 2005-09-09 2021-05-25 Labopharm Barbados Ltd solid monolithic extended release pharmaceutical composition
PT1931346E (en) * 2005-09-09 2012-08-14 Angelini Labopharm Llc COMPOSITION OF TRAZODONE FOR ADMINISTRATION ONCE A DAY
CA2648495C (en) * 2006-04-26 2016-07-05 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
HRP20161307T1 (en) 2008-05-09 2016-12-02 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
EP2293794B1 (en) 2008-05-27 2013-05-22 The University of Melbourne Methods of treating mammals with eustachian tube dysfunctions
MY161550A (en) * 2008-10-27 2017-04-28 Alza Corp Extended release oral acetaminophen/tramadol dosage form
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
PE20120631A1 (en) 2009-07-22 2012-06-06 Gruenenthal Chemie HANDLING RESISTANT DOSAGE FORM FOR OPIOIDS SENSITIVE TO OXIDATION
CN102821757B (en) 2010-02-03 2016-01-20 格吕伦塔尔有限公司 By extrusion mechanism for powdery medicine compositions
AR082862A1 (en) 2010-09-02 2013-01-16 Gruenenthal Gmbh ALTERATION RESISTANT DOSAGE FORM INCLUDING AN ANIONIC POLYMER
PL2611426T3 (en) 2010-09-02 2014-09-30 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
KR20140053159A (en) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 Tamper-resistant tablet providing immediate drug release
HRP20171458T1 (en) 2011-07-29 2017-11-17 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
JP6117249B2 (en) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Tamper resistant dosage forms comprising a pharmacologically active compound and an anionic polymer
PT2838512T (en) 2012-04-18 2018-11-09 Gruenenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
BR112015026549A2 (en) 2013-05-29 2017-07-25 Gruenenthal Gmbh tamper-proof dosage form containing one or more particles
EA032465B1 (en) 2013-07-12 2019-05-31 Грюненталь Гмбх Tamper-resistant oral pharmaceutical dosage form containing ethylene-vinyl acetate polymer and process for the production thereof
HK1224189A1 (en) 2013-11-26 2017-08-18 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
HK1246173A1 (en) 2015-04-24 2018-09-07 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
KR102536696B1 (en) * 2016-05-05 2023-05-25 어퀘스티브 테라퓨틱스, 아이엔씨. Pharmaceutical Compositions with Enhanced Permeability
KR20190005199A (en) 2016-05-05 2019-01-15 어퀘스티브 테라퓨틱스, 아이엔씨. Enhanced delivery fffffrin composition
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
DE19530575A1 (en) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Rapidly disintegrating drug form of tramadol or a tramadol salt
DK1009387T3 (en) * 1997-07-02 2006-08-14 Euro Celtique Sa Long-release stabilized tramadol formulations
DE10015479A1 (en) * 2000-03-29 2001-10-11 Basf Ag Solid oral dosage forms with delayed release of active ingredient and high mechanical stability
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
DE10108122A1 (en) * 2001-02-21 2002-10-02 Gruenenthal Gmbh Medicines based on tramadol

Also Published As

Publication number Publication date
WO2004037222A2 (en) 2004-05-06
IL168114A (en) 2011-05-31
NO20052479D0 (en) 2005-05-23
RU2005115855A (en) 2006-01-20
WO2004037222A3 (en) 2005-09-22
RU2328275C2 (en) 2008-07-10
CA2503155A1 (en) 2004-05-06
NO20052479L (en) 2005-05-23
PT1594460E (en) 2008-06-27
KR20050083816A (en) 2005-08-26
AU2003275855A1 (en) 2004-05-13
JP2006507277A (en) 2006-03-02
AU2003275855B2 (en) 2009-04-23
UA84277C2 (en) 2008-10-10

Similar Documents

Publication Publication Date Title
AR045972A1 (en) FORMULATIONS OF RELEASE OF SUSTAINED LIBERATION WITH EFFECTIVENESS OF 24 HOURS
PE20040134A1 (en) PRAMIPEXOL ONCE-A-DAY DOSAGE FORM
MX2015017307A (en) USE OF PRIDOPIDINE IN HIGH DOSE FOR THE TREATMENT OF HUNTINGTON'S DISEASE.
AR068185A1 (en) COMPOSITIONS OF LAMOTRIGIN ORAL DISINTEGRATION TABLETS
ES2530719T3 (en) Oxycodone formulations to be administered once a day
BRPI0414907A (en) injectable, oral or topical sustained release pharmaceutical formulations
BRPI0516718A (en) modified release ibuprofen dosage form
UY27533A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING OXIBUTININE
AR051099A1 (en) THERAPEUTIC COMBINATIONS THAT INCLUDE POLY INHIBITORS (ADP-RIBOSA) POLYMERASES
AR059723A2 (en) COMPOSITION OF HIGH DOSE OF IBANDRONATO
BRPI0510936A (en) controlled-release formulations of active substance containing vardenafil
MX2007006212A (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form.
AR039164A1 (en) VENLAFAXINE SALTS OF LOW WATER SOLUBILITY
CO6270217A2 (en) GALENIC FORMULATIONS OF ALISQUIRENO AND VALSARTAN
ATE505203T1 (en) PHARMACEUTICAL COMBINATION OF ALISKIREN AND VALSARTAN
AR045289A1 (en) ORAL DOSAGE FORM OF CONTROLLED RELEASE THAT INCLUDES 4- (2-DI-N-PROPILAMINOETIL) - 2 (3H) -INDOLONE (ROPI-NIROL) AND USE OF SUCH DOSAGE FORM FOR THE PREPARATION OF A MEDICINAL PRODUCT
PE20060588A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING FLIBANSERIN
PT1185253E (en) METHOD OF ORAL ADMINISTRATION FOR ADMINISTRATION OF A FIXED COMBINATION OF TRAMADOL AND DICLOFENAC
MX2007000117A (en) A COMBINATION COMPOSITION.
BR0013719A (en) Controlled-release oral dosage, suitable for oral administration
AR046410A1 (en) PHARMACEUTICAL COMPOSITIONS FOR MODIFIED LIBERATION OF MODAFINILO
AR054595A1 (en) GUANFACINE PHARMACEUTICAL FORMULATIONS / COMPOSITIONS APPROPRIATE FOR DAILY ADMINISTRATION FORM IN A SINGLE DOSE
BR0315659A (en) Oral pharmaceutical composition for once daily administration for controlled release of tramadol or a salt thereof
AR065139A1 (en) MEDICATION FOR THE TREATMENT OF ENDOMETRIOSIS
ECSP077843A (en) PRURITE TREATMENT OR PREVENTION

Legal Events

Date Code Title Description
FB Suspension of granting procedure